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OBJECTIVE—Humans with functional variants in the melano-
cortin 4 receptor (MC4R) are obese, hyperphagic, and hyperin-
sulinemic but have been reported to have no difference in energy
expenditure.
RESEARCH DESIGN AND METHODS—We investigated the
association of two MC4R variants, Arg165Gln (R165Q) and A
insertion at nucleotide 100 (NT100), with adiposity in 3,074
full-heritage Pima Indians, a subset of whom had metabolic
measures including 24-h energy expenditure (n  252) and
resting metabolic rate (RMR) (n  364).
RESULTS—Among the 3,074 subjects, 43 were heterozygous for
R165Q and 14 for NT100 (frequency  0.007 and 0.002). Mean (
SD) BMI was higher among subjects with R165Q (39.3  8.6
kg/m
2) or NT100 (41.2  7.8) than subjects without either variant
(37.1  8.4) (P  0.04 and 0.02, adjusted for age, sex, and birth
year and accounting for family membership). The 24-h energy
expenditure (four with NT100; three with R165Q) or RMR (six
with NT100; two with R165Q) was lower in heterozygous sub-
jects but only met statistical signiﬁcance when heterozygous
subjects were combined and compared with subjects without
either variant: least-squares means, 2,163 kcal/24 h (95% CI
2,035–2,291) vs. 2,307 kcal/24 h (2,285–2,328), P  0.03 for 24-h
energy expenditure, and 1,617 kcal/24 h (1,499–1,734) vs. 1,754
kcal/24 h (1,736–1,772), P  0.02 for RMR; adjusted for age, sex,
fat-free mass, and fat mass). For RMR, this difference persisted,
even after accounting for family membership.
CONCLUSIONS—Pima Indians heterozygous for R165Q or
NT100 in MC4R have higher BMIs and lower energy expenditure
(by 140 kcal/day), indicating that lower energy expenditure
was a component of the increased adiposity. Diabetes 57:
3267–3272, 2008
E
nvironment plays an important role in the devel-
opment of obesity, but considerable evidence
exists for a genetic contribution to body weight
(1). Several genes including the melanocortin 4
receptor (MC4R) located on chromosome 18q22 have been
identiﬁed as monogenic causes of obesity in humans (2).
Many of the identiﬁed variants in MC4R lead to partial or
complete loss of receptor activity (3). Mice lacking MC4R
are obese, are hyperinsulinemic, have increased food
intake (4), and have lower energy expenditure (5). Hu-
mans with MC4R mutations are obese, are hyperinsuline-
mic, and have increased food intake, but no difference in
energy expenditure has been reported (3).
The Pima Indians of southern Arizona have a high
prevalence of obesity (6). Sequencing of the coding region
of MC4R in 300 severely obese and 126 nonobese Pima
Indians identiﬁed 10 individuals (all obese) heterozygous
for a previously characterized G-to-A substitution at nu-
cleotide 165 (R165Q) that leads to partial inactivation of
MC4R (3). Three additional individuals (all obese) were
found to be heterozygous for a novel single-base insertion
(A) at nucleotide 100 (NT100) that predicts a frameshift
resulting in a premature STOP (TGA) at codon 37 (7). A
premature STOP codon at this position would produce a
truncated protein lacking critical ligand binding and trans-
membrane domains (3). Previously described variants
(V103I and I251L) found to be protective against obesity
(8,9) were not identiﬁed in this population. In the current
study, we investigated the prevalence of the MC4R func-
tional missense R165Q and the frameshift mutation in a
population-based survey of full-heritage Pima Indians, and
their association with BMI and in vivo measures of energy
expenditure and insulin action.
RESEARCH DESIGN AND METHODS
Every 2 years since 1965, members of the Gila River Indian Community age
5 years are invited to participate in a longitudinal study of diabetes and its
complications. This population is dynamic in that individuals may enter and
leave over the course of the study. After gaining informed consent, each
participant undergoes an examination, including measurements of height and
weight and a 75-g oral glucose tolerance test. Diabetes was diagnosed
according to 1999 World Health Organization criteria (10). DNA from 3,074
full-heritage Pima Indians from 1,676 sibships was used for genotyping in the
present study. An individual’s highest recorded BMI (i.e., maximum BMI)
during the longitudinal study was used to compare genotypes regardless of
diabetes status. Maximum BMI was chosen to attempt to fully capture the
propensity to increased adiposity. For all subjects, 59% were female, age
(mean  SD) was 35.4  13.0 years, the mean maximum BMI was 37.2  8.5
kg/m
2, and 36% had type 2 diabetes. We also analyzed the subset of individuals
for whom we had BMI measurements before diabetes development and
identiﬁed the maximum BMI from among the nondiabetic exams. This group
consisted of 2,603 individuals (mean age 34.6  12.7 years, 58% female, mean
maximum BMI 37.3  8.6 kg/m
2).
Clinical studies. Volunteers from the Gila River Indian Community also
participate in inpatient studies examining the pathophysiology of type 2
diabetes and obesity. After gaining informed consent, volunteers are admitted
to the clinical research unit and are fed a weight-maintaining diet (calories
from carbohydrate, fat, and protein 50, 30, and 20%, respectively) and abstain
from strenuous exercise. After 3 days, volunteers undergo a 75-g oral glucose
tolerance test (after a 12-h overnight fast). Nondiabetic volunteers then
undergo tests to assess body composition, insulin action in vivo, and energy
expenditure. All studies were approved by the Institutional Review Board of
the National Institute of Diabetes and Digestive and Kidney Diseases.
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underwater weighing with simultaneous determination of residual lung vol-
ume by helium dilution (11) or by total-body dual-energy X-ray absorptiometry
(DPX-L Lunar Radiation, Madison, WI) (12). Percent body fat, fat-free mass
(FFM), and fat mass were calculated; measurements using the two different
methods were made comparable using a previously derived equation (13).
Measurement of energy expenditure
24-h respiratory chamber. The measurement of energy expenditure in the
respiratory chamber has previously been described (14). Brieﬂy, volunteers
entered the chamber at 0745 h after an overnight fast and remained therein for
23 h. Meals were provided at 0800, 1130, 1700, and 2000 h (evening snack).
Because of the conﬁnement within the chamber, only 80% of the calories from
the weight-maintaining diet on the metabolic ward were provided in the
respiratory chamber. Fresh air was drawn through the chamber, and CO2
production and O2 consumption were measured and calculated every 15 min
and extrapolated for a 24-h interval. Energy expenditure over the 24 h (24-h
energy expenditure) was calculated as previously described (14). Spontane-
ous physical activity (SPA) was detected by radar sensors and expressed as
percentage of time over the 24-h period in which activity was detected.
Sleeping metabolic rate (sleep energy expenditure) was deﬁned as the average
energy expenditure of all 15-min periods between 2330 and 0500 h during
which spontaneous physical activity was 1.5%. Carbon dioxide production
(VCO2) and oxygen consumption (VO2) were calculated for every 15-min
interval and extrapolated for the 24-h interval. The 24-h respiratory quotient
was calculated as the ratio of the 24-h VCO2 and the 24-h VO2. Carbohydrate
and lipid oxidation rates were calculated from the 24-h respiratory quotient
accounting for protein oxidation (calculated from 24-h urinary nitrogen
excretion) (15).
Resting metabolic rate. Before starting the euglycemic-hyperinsulinemic
clamp, a clear plastic ventilated hood was placed over the volunteer’s head.
Room air was drawn through the hood, and ﬂow rate was measured. A
constant fraction of expired air was withdrawn and analyzed for O2 and CO2
content. The O2 analyzer was a zirconium cell analyzer and the CO2 an
infrared analyzer (Applied Electrochemistry, Sunnyvale, CA). The analyzers
were connected to a computer that recorded continual integrated calorimetric
measurements every 5 min for the hour before the start of the clamp
procedure. Energy expenditure was calculated using the equations of Lusk
(16) for the 40 min before the start of the clamp.
Measurement of insulin action. Insulin action was assessed at physiologic
insulin concentrations during the hyperinsulinemic-euglycemic clamp tech-
nique (17). Brieﬂy, after an overnight fast, primed (30 Ci) continuous (0.3
Ci/min) infusion of [3-
3H]glucose infusion was started to determine endog-
enous glucose output. Two hours after starting the isotope infusion, a primed
continuous intravenous insulin infusion was administered for 100 min at a rate
of 40 mU/m
2 body surface area per min (low dose), followed by a second
100-min infusion at 400 mU/m
2 body surface area per min (high dose). These
infusions achieved steady-state insulin concentrations of 143  42 and 1,714 
1,571 mU/l (mean  SD), respectively. Plasma glucose concentrations were
maintained at 100 mg/dl with a variable infusion of 20% dextrose solution.
Blood samples for measurement of [3-
3H]glucose speciﬁc activity were
collected at the end of the basal period and every 10 min during the ﬁnal 40
min of the low-dose insulin infusion. Endogenous glucose output was calcu-
lated using Steele’s equation (18). As described previously, the rate of total
insulin-stimulated glucose disposal (M) was calculated for the last 40 min of
the low-dose (M-low) and high-dose (M-high) insulin infusions. M-low was
corrected for mean glucose and insulin concentrations and endogenous
glucose output during the ﬁnal 40 min of the insulin infusion (19,20). M-high
was corrected for the mean glucose concentration, and endogenous glucose
output was assumed to be 0. All measurements derived from the glucose
clamp were normalized to estimated metabolic body size (estimated meta-
bolic body size or FFM  17.7 kg) (21).
Analytical measurements. Plasma glucose concentration was determined
by the glucose oxidase method (Beckman Instruments, Fullerton, CA). Plasma
insulin concentrations were measured by the Herbert modiﬁcation of the
method of Yalow and Berson (22,23), by an automated autoanalyzer (ICN
Radiochemicals, Costa Mesa, CA), or by an automated immunoassay (Access,
Beckman Instruments). Values from the ﬁnal two assays were regressed to the
original assay.
Genotyping. DNA was genotyped by the method of Taqman Alleleic Discrim-
ination (Applied Biosystems) for the G/A variant that predicts the R165Q and
was genotyped by the method of SNPlex (Applied Biosystems) for the single
base (A) insertion at nucleotide 100. DNA from all individuals genotyped as
heterozygous for either of these mutations was directly sequenced to conﬁrm
their genotype using the Big Dye Terminator (Applied Biosystems) on an
automated DNA capillary sequencer (model 3730xl; Applied Biosystems).
Sequence information for all oligonucleotide primers and probes is available
upon request.
Statistical analysis. In the population study, maximum BMI and weight were
adjusted for age, sex, and birth year (to account for population changes in BMI
over time) and analyzed for association using generalized estimating equa-
tions to account for family membership (by modeling the correlation among
family members). Height was analyzed in the same way but adjusted only for
sex and birth year. To satisfy the assumptions of linear regression, the
logarithm BMI was analyzed in all models; for simplicity of interpretation,
unadjusted mean BMI is reported but P values are derived from the models.
Cross-sectional data were analyzed for the subset with energy expenditure
and insulin action measurements. Linear regression models were used to
calculate adjusted least-squares means and 95% CIs for the energy expenditure
(24-h energy expenditure, sleep energy expenditure, or RMR) and insulin
action (M-low or M-high). Measurements were adjusted for covariates by
genotype. M-low and M-high were log transformed to approximate a normal
distribution. Energy-expenditure measurements were also adjusted for the
same covariates using generalized estimating equations to account for family
membership.
RESULTS
Population survey. In the population study of full-
heritage Pima Indians (n  3,074), 14 individuals had the A
insertion at nucleotide 100 (minor allele frequency 0.002)
and 43 individuals had the R165Q substitution (minor
allele frequency 0.007). Among these full-heritage Pima
Indians, none were homozygous for either variant or
compound heterozygous for the two variants. BMI ( SD)
was higher among subjects heterozygous for the NT100
compared with subjects without this variant (41.2  7.8 vs.
37.1  8.4 kg/m
2, P  0.04). BMI was also higher among
subjects heterozygous for R165Q compared with subjects
without this variant (39.3  8.6 vs. 37.1  8.4 kg/m
2, P 
0.02). Body weight was also signiﬁcantly higher among the
TABLE 1
Characteristics of subsets of full-heritage Pima Indians with measurements of energy expenditure and insulin action by the MC4R variant
24-h energy expenditure Sleep energy expenditure
Control NT100 R165Q Control NT100 R165Q
n (M/F) 245 (129/116) 4 (1/3) 3 (3/0) 237 (122/115) 4 (1/3) 3 (3/0)
Age (years) 26.3  6.6 21.2  2.1 31.7  6.1 26.2  6.5 21.2  2.1 31.7  6.1
Height (cm) 166.0  7.9 167  5.4 175  0.5* 166.0  7.9 167.0  5.4 175  0.5*
Weight (kg) 92.9  24.1 99.5  7.4 119.4  21.1* 93.3  24.3 99.5  7.4 119.4  21.1
BMI (kg/m²) 33.7  8.6 35.8  4.7 38.7  6.7 33.5  8.6 35.8  4.7 38.7  6.7
% Fat 33.3  9.0 36.2  10.9 36.1  5.7 33.5  8.9 36.2  10.9 36.1  5.7
FFM (kg) 60.7  12.4 63.2  9.4 75.7  9.7* 60.8  12.7 63.2  9.4 75.7  9.7*
Fat mass (kg) 32.2  14.8 36.4  12.4 43.7  13.0 32.4  14.8 36.4  12.4 43.7  13.0
Fasting plasma glucose (mmol/l) 4.88  0.55 4.78  0.43 4.55  0.61 4.94  0.55 4.78  0.43 4.55  0.61
2-h plasma glucose (mmol/l) 6.72  1.67 6.69  2.49 5.11  1.12 6.72  1.67 6.69  2.49 5.11  1.12
Data are means  SD. Control  neither variant; NT100  A insertion variant; R165Q  G-to-A substitution. *P  0.05 for comparison of
NT100 or R165Q to common variant using Wilcoxon’s rank-sum test.
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tended to be shorter (163.3  6.8 vs. 164.6  8.4 cm, P 
0.02), whereas heterozygotes for R165Q were slightly taller
(166.8  8.6 vs. 164.6  8.4, P  0.14). Because of the
relatively small number of subjects heterozygous for either
variant, BMI was also analyzed after combining heterozy-
gotes for either variant (57 of 3,074  1.8% of individuals
were heterozygous for either variant). Heterozygotes for
either variant had a signiﬁcantly higher mean BMI than
subjects without either variant (39.8  8.6 vs. 37.1  8.4
kg/m
2, P  0.002, adjusted for age, sex, and birth year
using generalized estimating equations to account for
family membership). If the analysis was restricted to
individuals measured when nondiabetic, 46 of 2,649 (1.7%)
were heterozygous for either variant, and the difference in
BMI versus those without either variant remained (39.5 
8.0 vs. 36.2  8.2 kg/m
2, P  0.0003). In the nondiabetic
exams for each variant separately, the trend was the same
(for NT100 [n  12], 38.4  6.7 vs. 36.2  8.2 kg/m
2, P 
0.12; for the R165Q [n  34], 39.8  8.6 vs. 36.2  8.2
kg/m
2, P  0.0009).
Energy expenditure and insulin action. Table 1 shows
the baseline variables for the subsets who had measure-
ments of energy expenditure and insulin action displayed
for each heterozygote. Because of the smaller numbers in
these subsets, differences in adiposity between the vari-
ants was not always signiﬁcant. The same seven heterozy-
gotes are present in the 24-h energy expenditure and sleep
energy expenditure subsets. One heterozygote had mea-
surements of 24-h energy expenditure, sleep energy expen-
diture, and RMR and is included in each analysis. All of the
heterozygotes who had measurements of RMR also had
measurements of insulin action. Energy expenditure (ad-
justed for age, sex, FFM, and fat mass) and insulin action
(adjusted for age, sex, and percent body fat) measure-
ments are shown in Table 2 for both the individual and
combined variants with and without accounting for family
membership. For the 24-h energy expenditure measure-
ments, additional adjustment for spontaneous physical
activity or energy balance did not alter the results (data
not shown). Energy expenditure measures were consis-
tently (although not signiﬁcantly) lower for each hetero-
zygote. Because of each heterozygote’s association with
increased BMI in the population study, they were analyzed
together (combined group in Table 2). All energy expen-
diture measurements were signiﬁcantly lower in the com-
bined group compared with the common variants. After
accounting for family membership, the differences were
attenuated, although they were still quite signiﬁcant for
RMR. Measures of insulin action did not display a similar
consistent pattern, although M-low (but not M-high) was
signiﬁcantly lower in the NT100 heterozygotes. Figure 1
shows plots of measured energy expenditure versus FFM
for each variant, demonstrating relatively lower energy
expenditure in the majority of the heterozygotes compared
with individuals of comparable FFM with the common
genotype. There were no differences in 24-h respiratory
quotient or lipid oxidation after adjustment for the same
covariates (data not shown).
DISCUSSION
Previous studies of the frequency of functional MC4R
variants have been performed in groups selected for
obesity (24,25), but in a more general population study,
these variants were not associated with higher BMI (26).
For nonfunctional variants, meta-analysis of a V103I MC4R
polymorphism in predominantly Caucasian subjects con-
cluded that the isoleucine allele was modestly associated
with protection from obesity (9,27). This locus is mono-
morphic for the valine allele in the 426 Pima Indians in
whom the gene was sequenced. A recent meta-analysis in
a large group of Europeans found that a range of func-
tional MC4R variants were more common in obese than
lean individuals (28). In a German population study,
R165Q was rare (minor allele frequency 1.2  10
4) and
the individual was not obese (26). In our general popula-
tion study of full-heritage Pima Indians, the percentage of
individuals carrying either the R165Q or the NT100 is 1.8%,
and their association with higher BMI was clear. This was
even more pronounced in the analysis excluding subjects
with type 2 diabetes, presumably because of the inﬂuence
of diabetes itself or associated medications on weight.
Furthermore, in a subset of Pima Indians who also under-
went metabolic studies, we found that energy expenditure
tended to be lower (although not signiﬁcantly so) among
individuals heterozygous for one of these two variants.
The R165Q variant has known functional consequences
(3). Although not proven, we propose that the NT100 also
has functional consequences because it predicts a trun-
cated receptor lacking critical domains. Therefore, we
combined these rare variants to obtain additional statisti-
cal power and, in so doing, we have shown for the ﬁrst
time in humans that energy expenditure, adjusted for age,
sex, FFM, and fat mass is lower in individuals heterozy-
gous for either variant. The lower energy expenditure (of
110–140 kcal/day) was apparent in analyzing 24 h and
sleep energy expenditure (both measured in our respira-
TABLE 1
Continued
RMR M-low M-high
Control NT100 R165Q Control NT100 R165Q Control NT100 R165Q
356 (203/153) 6 (5/1) 2 (1/1) 350 (192/158) 3 (1/2) 6 (5/1) 314 (177/137) 3 (1/2) 5 (4/1)
26.1  6.0 27.9  4.9 20.6  2.7 26.2  6.0 21.6  2.5 27.9  4.9 26.2  6.1 21.6  2.5 26.8  4.6
166.1  8.1 168.3  4.7 161  9.5 165.8  8.2 161.4  6.8 168.3  4.7 166.0  8.5 161.4  6.8 168.6  5.2
94.0  22.7 103.3  10.9 91.4  7.2 95.0  23.0 90.9  5.2 103.4  10.9 94.0  22.2 90.9  5.2 102.1  11.7
34.0  7.8 36.5  4.0 35.0  1.4 34.5  7.7 34.9  1.0 36.5  4.0 34.0  7.4 34.9  1.0 35.9  4.1
33.1  8.7 32.7  8.1 29.8  12.8 33.8  8.4 33.3  10.9 32.7  8.0 33.4  8.4 33.3  10.9 34.2  8.0
61.8  12.4 69.4  10.3 64.7  16.8 62.0  12.7 61.0  13.5 69.4  10.3 61.7  12.6 61.0  13.5 66.9  9.3
32.2  13.7 33.9  9.6 26.7  9.6 33.1  13.6 29.9  8.7 34.0  9.6 32.3  13.1 29.9  8.7 35.2  10.2
5.00  0.55 5.03  0.21 4.75  0.82 5.00  0.55 5.04  0.77 5.03  0.21 4.98  0.54 5.04  0.77 4.98  0.21
6.89  1.72 6.90  1.27 5.39  2.28 6.94  1.67 5.98  1.91 6.90  1.27 6.91  1.71 5.98  1.91 7.08  1.34
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DIABETES, VOL. 57, DECEMBER 2008 3269tory chamber) and replicated by measurements of RMR,
using a ventilated hood, on a separate day.
In mice, the MC4R is critical in the role of regulating
energy homeostasis and is abundant in the hypothalamic
paraventricular nucleus. MC4R knockout mice have early-
onset obesity, hyperphagia, hyperinsulinemia, and hyper-
glycemia, with heterozygotes having an intermediate
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FIG. 1. A: 24-h energy expenditure (EE) versus FFM. B: Sleep energy
expenditure versus FFM. C: RMR versus FFM. , neither variant; Œ,
NT100 variant; F, R165Q variant.
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humans was documented with discovery of a frameshift
mutation associated with autosomal dominantly inherited
obesity (29,30). The clinical phenotype of these individuals
(including both homozygous and heterozygous subjects)
included early-onset obesity and excessive hunger during
childhood with food-seeking behavior (2). Children with
MC4R variants ate nearly three times as many calories as
their unaffected siblings in studies evaluating ad libitum
food intake (3), although this hyperphagia decreased to-
ward adulthood. In these same studies, RMR, measured by
indirect calorimetry, was not different based on compari-
sons with age- and sex-speciﬁc equations corrected for
FFM (2,3).
Our data indicate that reduced energy expenditure (by
110–140 kcal/day) is part of the clinical phenotype of
adults heterozygous for rare obesity-associated MC4R
variants. Mice with MC4R knockout mutations have re-
duced energy expenditure (5), but this is not due to
reduced core body temperature or an inability to thermo-
regulate. MC4R knockout mice also have lower energy
expenditure compared with leptin knockout (OB/OB)
mice (27). Although data on the association between
MC4R variants and measured energy expenditure is lim-
ited in humans, the Val103Ile MC4R polymorphism, which
has been negatively associated with obesity (27,31), was
also associated with higher RMRs in a separate study (32).
Although RMR was higher in this prior report, BMI was not
different between individuals with the Val versus the 103lle
allele, and individuals with the 103Ile allele tended to gain
more weight over time (32). Furthermore, unlike our
studies, RMR was not performed after an inpatient period
of weight stabilization. Therefore, increased food intake
could account for the increased RMR. Despite recent
evidence in mice for a role of MC4R in lipid metabolism
(33), we did not ﬁnd differences in respiratory quotient or
lipid oxidation in MC4r heterozygotes.
Evidence for a direct effect of MC4R on energy expen-
diture comes from rodent studies. In particular, MC4R is
important in activating the sympathetic nervous system
(34,35). MC4R mediates the central response to leptin-
induced expression of uncoupling protein 1 (UCP1) in
brown adipose tissue of rats (35), and sympathetic nerve
activity in rats increased when an MC4R agonist was given
(34). Activation of the sympathetic nervous system in-
creases basal energy metabolism (36); therefore, loss of
function in MC4R with resulting lower sympathetic tone
would explain the lower energy expenditure in these
individuals. It is not clear, however, if the lower energy
expenditure in these adults precedes (and is therefore
causative of their increased weight or whether this lower
energy expenditure represents a failure to adapt to in-
creased body size (thus making it difﬁcult for these
individuals to lose weight). Leptin concentrations and
sympathetic nervous system activity increase with body
size, thereby increasing energy expenditure and braking
further weight gain (37).
Although this analysis concentrates on the differences
noted in energy expenditure, increased food intake (hy-
perphagia) may still account for a portion (perhaps even
most) of the weight gain and adiposity among individuals
with these variants. Our study did not include measure-
ment of ad libitum food intake, and more careful under- or
overfeeding studies would be needed to elucidate the
relative contribution of each factor. In addition, while the
energy-expenditure differences were relatively large, the
EE measurements were performed on individuals on
weight-maintaining diets in an inpatient setting, and were
conﬁrmed using measurements done at separate times on
different individuals (only one individual with a variant
was in the group with both 24-h energy expenditure and
RMR), given the small numbers, these differences should
be interpreted with caution. The adjusted mean difference
in energy expenditure between heterozygotes and those
with the common genotype was 110–140 kcal/day. If this
deﬁcit was maintained over a year, it would amount to
40,150–51,000 kcal difference per year.
Our data indicate that full-heritage Pima Indians het-
erozygous for either a frameshift or a functional missense
MC4R variant have higher BMI values and lower 24-h,
sleeping, and resting energy expenditure. This is one of the
clearest examples in humans of a genotype resulting in
reduced energy expenditure and provides a link between
the melanocortin system and energy expenditure. Further
understanding of how this system affects energy expendi-
ture may provide important clues for advances in obesity
treatment and prevention.
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